Home / People / Hadi Mirzai
Portrait ofHadi Mirzai

Hadi Mirzai

Senior Associate

CMS von Erlach Partners Ltd
Dreikönigstrasse 7
P.O. Box
8022 Zurich
Languages German, English

Hadi Mirzai's practice covers all aspects of Swiss and EU antitrust law (e.g. horizontal and vertical agreements, dominance abuse, merger control and civil antitrust law). He represents clients in administrative proceedings before the Swiss Competition Commission and courts. Hadi Mirzai has advised clients in a wide range of industries and is particularly experienced in assisting clients in dawn raids as well as in the implementation of compliance programs. In addition to competition law, he focuses on intellectual property, technology law and life sciences. 

Before joining CMS in 2017, Hadi Mirzai has worked in the Construction Division of the Secretariat of the Swiss Competition Commission and gained expertise in competition matters related to the construction sector and public procurement.

more less

Relevant experience

  • Advice to international automotive group in antitrust proceedings before the Swiss Competition Commission regarding horizontal information exchange and price fixing (including amicable settlement with the authority)
  • Representation of financial services provider in investigation regarding an alleged boycott of Apple Pay and other international mobile payment solutions
  • Antitrust advice to leading payment industry company held by competing companies from the financial sector on the implementation of various projects
  • Representation of construction company in the so far largest bid-rigging investigation in Switzerland (canton of Grisons)
  • Advice to ancillary construction trade association on the implementation of industry guidelines
more less

Memberships & Roles

  • Zurich Bar Association (ZAV)
  • Swiss Bar Association (SAV)
  • Antitrust Law Association (Studienvereinigung Kartellrecht e.V.)


more less


more less


  • 2020 Bar admission
  • 2016 Master of Law, University Zurich
  • 2015 Bachelor of Law, University Zurich
more less
10 key aspects of the revised EU competition law in the field of distribution...
The new Vertical Block Exemption Regulation (VBER) and the new accompanying Vertical Guidelines (VGL) were published on 10 May 2022. The new VBER will enter into force on 1 June 2022 and apply for the next twelve years. The new VBER/VGL introduce sev


CMS advises Synlab on the sale of its Swiss business to Sonic Healthcare
SYNLAB and Sonic have announced the sale of SYNLAB Suisse SA to Sonic Healthcare for a purchase price of CHF 150m, having received the required approval of the Swiss antitrust authority. Closing of the transaction expected for 3 July 2023.
CMS advises the owner family on the sale of a majority stake in SCHURTER...
The Swiss investor Capvis, which specialises in medium-sized investments, acquires a majority stake in the Lucerne-based SCHURTER Group. The founding and previous owner family continues to hold a stake in the company and is represented on the board of directors by Thomas Schurter.
CMS advises US technology company Bruker on entering into a corporate strategic...
Zurich, 4 January 2023 Bruker Corporation, a NASDAQ-listed US tech company, has entered into a partnership with Swiss firm Biognosys AG to deliver advanced proteomics CRO services for US biopharma and biomarker customers. As part of the partnership, Bruker has made a ma­jor­ity-own­er­ship investment in Biognosys AG. Biognosys is a leader in the development of proteomics technologies and solutions for pharmaceutical and biotech research. The strategic partnership is expected to create unique synergies between Biognosys’ portfolio of proteomics services, software and kits, and Bruker’s pioneering timsTOF platform. As a result of the partnership, Biognosys plans to open its first advanced proteomics CRO services laboratory in the US. Details of the transaction were not disclosed. An international CMS team headed by Stefan Brunnschweiler and Dr Hendrik Hirsch advised Bruker on all legal aspects of the transaction. Bruker has also relied on the expertise of CMS in the past. Previous work by CMS for Bruker Corporation included providing legal advice on the company’s investment in PreOmics. CMS Switzer­land­Stefan Brunnschweiler, Lead Partner, Zurich, Corporate / M&AAndrea Relly, Senior Associate, Corporate / M&ASamuel Felix Gang, Senior Associate, Corporate / M&APascal Stocker, Senior Associate, Corporate / M&AAnna Mast, Associate, Corporate / M&ADr Simone Brauchbar Birkhäuser, Partner, Intellectual PropertyMark Cagienard, Partner, TaxSarah Keller, Senior Associate, Employment & PensionsHadi Mirzai, Senior Associate, Life Sciences and Com­pet­i­tion­Valentina Balaj, As­so­ci­ate, Reg­u­lat­ory / ComplianceCMS Ger­manyDr Hendrik Hirsch, Lead Partner, Frankfurt/Main, Corporate/M&ADr Berrit Roth-Mingram, Senior Associate, Frankfurt/Main, Corporate/M&ADr Thomas Hirse, Partner, Dus­sel­dorf, In­tel­lec­tu­al PropertySven Krause, Senior Associate, Dusseldorf, Intellectual Property
CMS advises Bruker on its investment in Navignostics
Bruker Corporation, a NASDAQ-listed US tech company in the analytical instrumentation sector, invests in Navignostics. Bruker led the CHF 7.5 million seed financing round, which was also joined by Think. Health Ventures, Ventura Biomed Investors and Zürcher Kantonalbank. Navignostics strives to support the selection of targeted and immuno-oncology therapies tailored to the tumour phenotype of individual cancer patients by using artificial intelligence driven software combined with single-cell resolved spatial proteomic tumour data. The funding will strengthen Navignostics' ability to collaborate with clinical, biotechnology and pharmaceutical partners and accelerate the development of its first diagnostic product.A team from CMS Switzerland, led by partner Stefan Brunnschweiler, advised Bruker on all legal matters of the transaction. Bruker is a longstanding CMS client and has been advised by CMS on several acquisitions and disposals in the past. CMS Switzer­land­Stefan Brunnschweiler, Partner, Corporate / M&APascal Stocker, Associate, Corporate / M&ADr Simone Brauchbar Birkhäuser, Counsel, Intellectual PropertyHadi Mirzai, Associate, Life Sciences and CompetitionSarah Keller, Associate, Employment 
CMS advises on joint venture between Voigt Holding AG and PHOENIX Pharma...
Zurich, 28 October 2022The Voigt Group and PHOENIX Pharma Switzerland have agreed to merge their subsidiaries, each active in pharmaceutical logistics and pharmaceutical wholesale sectors respectively, into a 50/50 joint venture. The two long-established and financially sound companies are an ideal fit with complementary offerings and competencies in the supply chain. Subject to approval by the Swiss Competition Commission, this joint venture will create a new, competent and sustainable player in the supply chain of the Swiss healthcare market.A CMS Switzerland team led by Dr Patrick Sommer provided comprehensive legal advice to Voigt Group on this joint venture. CMS Switzerland: Dr. Patrick Sommer, Partner, Lead, Corporate / M&A, Competition & EUAlain Raemy, Partner, Corporate / M&AMarquard Christen, Partner, Competition & EUDirk Spacek, Partner, Intellectual PropertyDr Simone Brauchbar Birkhäuser, Counsel, Intellectual PropertyHadi Mirzai, Associate, Life Sciences, Competition & EUAlexandra Stocker, Associate, Corporate / M&AAnna Mast, Associate, Corporate / M&ADr. Matthias Kuert, Associate, Banking & FinanceThomas Zweifel, Associate, Real EstateChristina Winter, Associate, Employment
Adverse effects of drugs and vaccines in Switzerland
1. Drug adverse effects: kinds of responsibility 1.1 Which are the main kinds of responsibility (contractual, in tort, criminal) of the following subjects with respect to adverse drugs reactions? A...
Spotlight on approaches for comprehensive compliance: New obligations for...
Because of the trend towards a stronger awareness of "corporate social responsibility", companies both in Switzerland and abroad are confronted with growing demands for responsible corporate governance...
Spotlight on approaches for comprehensive compliance: New obligations for...
Because of the trend towards a stronger awareness of Corporate Social Responsibility (CSR), companies both in Switzerland and abroad are confronted with growing demands for responsible corporate governance. The most recent example of legal developments in this area is the indirect counter-proposal to the federal popular initiative "the Responsible Business Initiative – Protecting human rights and the environment" ("Konzern­ver­ant­wor­tungsin­i­ti­at­ive"). With the expiry of the referendum deadline on 5 August 2021, new due diligence and reporting regulations on non-financial matters as well as in areas of conflict minerals and child labour are expected to come into force in Switzerland on 1 January 2022. In recent years, the Governance, Risk and Compliance (GRC) approach has been an efficient tool for companies with complex corporate structures to meet expanding regulatory requirements. By means of a comprehensive approach, the areas of Governance, Risk and Compliance have been merged and companies are well advised to examine their compliance structures critically and, if necessary, adapt them to the latest developments.
CMS advised HEB on the divestment of its stake in SIX listed Cicor to One...
Zurich, 19 July 2021 | HEB Swiss Investment AG, a Zurich-based holding company owned by a German private investor, has entered into an agreement to sell its major stake (29.3 %) in listed Cicor Technologies...
The Federal Supreme Court's judgment in the matter "Hors-Liste Medikamente...
On 21 April 2021, the Federal Supreme Court published a judgment against Pfizer regarding the sanction order of the Competition Commission (COMCO) in the matter Hors-Liste Medikamente (Pre­isem­p­fehlun­gen)...
Switzerland introduces the concept of relative market power and restricts...
On Friday, 19 March 2021, the Swiss parliament adopted in its final vote the amended parliamentary counter-proposal to the popular initiative "Stop the high price island - for fair prices". This counter-pro­pos­al...
CMS advised DP World on the acquisition of a 44% stake in swissterminal...
CMS advised DP World on the acquisition of a 44% stake in swissterminal Holding AG A team under the lead of Stefan Brunnschweiler has advised DP World, a Dubai-based global port operator, on the acquisition...